CORALVILLE, IA–(Marketwire – 12/21/09) – Vivakor, Inc. (OTC.BB: VIVK) — With the recent authorization of 13 new stem lines by the National Institutes of Health and another 96 new lines awaiting federal approval, combined with the Obama administration’s focus on funding research on these newly released stem cell lines (31 grants worth approximately $21 million have already been approved by the NIH), Vivakor and its biological handling division have a unique opportunity to seize on this suddenly red hot market. Vivakor’s Executive Chairman, Matt Nicosia, was quoted: “Vivakor’s VivaThermic division and its cryovials present a dramatic new tool for researchers in this incredibly important and commercially exploding field. We plan on playing a large role by establishing our cryovials as the new ‘gold standard’ for use in many of the research areas which utilize stem cells and cryopreservation of the cells.”
CORALVILLE, Iowa, Dec. 16 /PRNewswire-FirstCall/ — Vivakor, Inc. (OTC Bulletin Board: VIVK) has signed a Business Development agreement with Baker Consulting out of Walnut Creek, California and its affiliate group, Kyouko Group, Inc. out of South Florida. Baker Consulting has been retained by Vivakor to assist with business development, financing and assisting the company with its recently reported acquisition strategy. Specifically, Baker Consulting is exploring potential acquisition targets for Vivakor in the areas of ophthalmological devices and treatment solution companies as well as other targets aligned with Vivakor’s existing divisions. In addition to vetting and presenting specific opportunities, Baker Consulting is continuing to present financing opportunities for these transactions as well as for Vivakor’s existing operations.
Stocks are trading lower after wholesale inflation rose more than expected in November
Wholesale inflation rose more than expected in November, led by a surge in energy costs.
The increase likely will be discussed as Federal Reserve policymakers begin a two-day meeting on interest rates. The Fed is expected to keep rates unchanged when it releases a policy statement following the meeting Wednesday.
CALGARY, Alberta, Dec. 15, 2009 (GLOBE NEWSWIRE) — Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on Vivakor, Inc. (OTCBB:VIVK). Skymark Research is currently offering a complimentary trial subscription. To view our research go to: www.skymarkresearch.com.
CORALVILLE, Iowa, Dec. 14 /PRNewswire-FirstCall/ — Vivakor, Inc. (OTC Bulletin Board: VIVK) today announced the launch of its new website promoting its remarkable VivaThermic Vial at www.vivathermic.com. In addition to providing customers with the latest news and developments for its VivaThermic product line, Vivakor developed this site to be a valuable resource for its domestic and international customers, such as the highly respected Veritas Corporation of Tokyo, Japan, which signed an exclusive five year exclusive distribution agreement to distribute Vivakor’s VivaThermic products in Japan. Under the terms of the Agreement, Veritas will have exclusive distribution rights to all Vivakor’s VivaThermic Division products in Japan, including the recently released VivaThermic SUPER-150 and VivaThermic UTLRA-300 cryovials.
Stocks are higher following a bigger-than-expected rise in retail sales
Stocks are rising after a report on retail sales showed consumers are picking up their spending.
The Commerce Department says retail sales rose 1.3 percent in November, more than double the 0.6 percent increase economists had expected. Sales rose 1.1 percent in October.
The report is boosting hopes that consumers are starting to feel more comfortable opening up their wallets after months of building up their savings.